RESULTS At 12 weeks , the continuous administration group displayed decreases in BASDAI from 8 to 4 , in ASDAS from 3.8 to 2.6 , and in hs-CRP levels from 9.5 to 3.9 mg/l ; the intermittent administration group exhibited decreases in BASDAI from 7.6 to 6.0 , in ASDAS from 3.5 to 3.1 , and hs-CRP from 8.8 to 4.5 mg/l ( p < 0.05 ) .